Market Segmentation: Biologics, Biosimilars & Drug Classes
Within the Erythropoietin Drugs Market, the two main product segments are traditional biologics and newer biosimilars. Although biologics still command the larger share, biosimilars are rapidly gaining ground due to cost advantages and rising approvals.
Drug classes such as epoetin-alfa remain widely used across CKD and oncology applications, while darbepoetin-alfa—with its longer half-life—gains popularity for reduced dosing frequency. The diversification of product offerings is reshaping treatment strategies globally.
2 Views